Connection

Faye Hant to Female

This is a "connection" page, showing publications Faye Hant has written about Female.
Connection Strength

0.159
  1. Systemic Sclerosis and Perceptions of Quality in Primary Care. Am J Med Sci. 2016 05; 351(5):447-51.
    View in: PubMed
    Score: 0.028
  2. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009 Apr; 36(4):773-80.
    View in: PubMed
    Score: 0.018
  3. Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. Int J Rheum Dis. 2022 Feb; 25(2):163-174.
    View in: PubMed
    Score: 0.011
  4. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Rheumatol. 2021 06; 73(6):1005-1013.
    View in: PubMed
    Score: 0.010
  5. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2020 11; 72(11):1892-1896.
    View in: PubMed
    Score: 0.010
  6. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2020 01; 72(1):125-136.
    View in: PubMed
    Score: 0.009
  7. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis. 2020 03; 79(3):379-386.
    View in: PubMed
    Score: 0.009
  8. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019 12; 71(12):2059-2067.
    View in: PubMed
    Score: 0.009
  9. Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. Clin Rheumatol. 2020 Jan; 39(1):93-102.
    View in: PubMed
    Score: 0.009
  10. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
    View in: PubMed
    Score: 0.009
  11. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. J Rheumatol. 2017 06; 44(6):791-794.
    View in: PubMed
    Score: 0.008
  12. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
    View in: PubMed
    Score: 0.007
  13. Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. J Med Case Rep. 2015 Jun 10; 9:136.
    View in: PubMed
    Score: 0.007
  14. Factors associated with oral hygiene practices among adults with systemic sclerosis. Int J Dent Hyg. 2014 Aug; 12(3):180-6.
    View in: PubMed
    Score: 0.006
  15. Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum. 2010 Jul; 62(7):2117-26.
    View in: PubMed
    Score: 0.005
  16. Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis Rheum. 2007 Oct; 56(10):3468-77.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.